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Background: Both inhibition of Plk1 and usage of 
metformin are reported to achieve strong anti-
neoplastic functions in many cancers including 
prostate cancer (PCa).  
Results: Plk1 inhibitor BI2536 synergizes with 
metformin in controlling PCa cell growth. 
Conclusion: Plk1 inhibition improves the anti-
neoplastic function of metformin in PCa through 
both signaling pathways and metabolic pathways.  
Significance: The proposed combinational therapy 
shows great potential for clinical trials.  
 
ABSTRACT: 
The widely used anti-diabetic drug 
metformin has been shown to exert strong anti-
neoplastic actions in numerous tumor types, 
including prostate cancer. In this study, we 
show that BI2536，a specific Plk1 inhibitor, acts 
synergistically with metformin in inhibiting 
prostate cancer cell proliferation. Furthermore, 
we also provide evidence that Plk1 inhibition 
renders prostate cancer cells carrying wild type 
p53 to be much more sensitive to low dose 
metformin treatment. Mechanistically, we 
found that co-treatment with BI2536 and 
metformin induces p53-dependent apoptosis 
and further activates the p53/Redd-1 pathway. 
Moreover, we also show that BI2536 treatment 
inhibited metformin-induced glycolysis and 
glutamine anaplerosis, both of which are 
survival responses of cells against mitochondrial 
poisons. Finally, we confirmed the cell-based 
observations using both cultured cell-derived 
and patient-derived xenograft studies. 
Collectively, our findings support another 
promising therapeutic strategy by combining 
two well-tolerated drugs against prostate cancer 
proliferation and the progression of androgen-
dependent prostate cancer to castration-
resistant stage. 
 
INTRODUCTION:  
Prostate cancer (PCa), the most common form 
of malignancy in men, causes the second leading 
cancer-related death of males in the United States 
(1). Because PCa cells require androgen for 
proliferation and development, androgen 
deprivation (castration) is an effective treatment for 
patients with late stage PCa. However, although 
nearly 80% of the patients initially respond to 
castration therapy well, castration-resistant 
prostate cancer (CRPC) eventually occurs in most 
of these patients after several years and then 
progresses to metastatic diseases (2-4). With very 
limited methods to treat advanced PCa, novel drugs 
with new cellular targets are urgently needed. 
Metformin is a widely used anti-diabetic drug 
to almost 120 million people to treat type 2 
diabetes. It alleviates hyperglycemia by lowering 
hepatic glucose production and increasing glucose 
uptake by peripheral tissues (5). Recently, 
increasing evidence suggests that metformin also 
decreases viability of various cancer cells and 
inhibits xenograft tumor growth in nude mice (6-
10). Of note, metformin usage was also shown to 
reduce the development of CRPC by one clinical 
trial, in which 3000 CRPC patients were analyzed 
(11). More importantly, the drug is inexpensive, 
well tolerated and actively participates in 
metabolism, which make it quite attractive in 
cancer therapeutics (12,13). However, there are 
still many issues need to be addressed before 
metformin can be widely used in cancer treatments. 
First, the detailed anti-neoplastic mechanisms 
behind this drug remain to be elucidated. 
Previously, the fundamental effect of metformin in 
cancer treatment was believed to be due to its 
activation of AMP-activated protein kinase 
(AMPK) and the subsequent inhibition of both cell 
cycle progression and mTORC1 (mammalian 
target of rapamycin complex I), a critical regulator 
of protein synthesis and cell proliferation (14-17). 
However, metformin was also shown to achieve the 
same effect via the p53/Redd-1 pathway 
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independent of AMPK in PCa cells (6,18). 
Furthermore, metformin inhibits mTORC1 in a 
Rag GTPase-dependent manner (19). More 
recently, another group reported that the inhibition 
of mTOR1 by metformin was due to the enhanced 
binding between PRAS40 and Raptor, both of 
which are components of the mTORC1, thus 
independent of AMPK (20). The second concern is 
that the intake of metformin into the cell requires 
the expression of organic cation transporter 1 
(OCT1) (21,22), and the concentrations of 
metformin used in the current in vitro or preclinical 
anti-proliferative studies were much higher than 
the recommended therapeutic dosage in humans 
(23). In other words, the positive results in animal 
studies cannot indicate the success in clinical trials 
if we are not using a similar dose level of 
metformin. Thus, how to increase the efficacy of 
this drug to avoid the high dosage-induced side 
effects and efficiently deliver it to desired organs 
should be the major tasks to make metformin a real 
candidate for cancer therapy. 
Polo-like kinase 1 (Plk1) is an essential 
serine-threonine kinase involved in many mitotic 
events, such as mitotic entry, bipolar spindle 
formation, and sister chromatid segregation (24). 
Plk1 is over-expressed in many types of human 
cancers and Plk1 inhibitors have been pre-
clinically evaluated as potential drugs for cancer 
treatment (25). BI2536, the first Plk1 inhibitor to 
enter clinical trials, has already been studied in 
phase I and II, and it is well tolerated in humans 
regardless of the limited therapeutic effects in some 
types of tumors (26-28). Of note, it was recently 
reported that Plk1 is up-regulated in androgen-
insensitive PCa cells and its inhibition leads to 
necroptosis (29). In addition, Plk1 not only 
promotes androgen receptor signaling (30), but 
also acts as a negative regulator of tumor 
suppressor p53 (31,32), which is crucial for 
mediating metformin treatment of PCa (18).  
In this report, we investigated a new 
therapeutic strategy against PCa using 
combinatorial treatment of metformin and Plk1 
inhibitor BI2536. In addition to both in vitro and in 
vivo observations, we also provide possible 
mechanisms for the synergy in signaling pathways 
and metabolic pathways. 
 
EXPERIMENTAL PROCEDURES 
Chemicals—BI2536 was purchased from 
Symansis NZ Ltd, New Zealand and dissolved in 
DMSO as working solution. Metformin was 
purchased from Sigma (D150959) and dissolved in 
distilled water. 
Cell Culture, virus infection and RNAi—
LNCaP, C4-2, DU145, PC3, 293A and RWPE-1 
cells were purchased from ATCC and cultured in 
37°C with 5% CO2. LNCaP and C4-2 cells were 
cultured in RPMI-1640 medium supplemented 
with 10% FBS, 100 units/ml penicillin and 100 
units/ml streptomycin. DU145, PC3 and 
HEK293A cells were cultured in Dulbecco’s 
Modified Eagle’s Medium. RWPE-1 cells were 
cultured in keratinocyte serum free medium 
(Gibco). Lentivirus constructs were generated and 
virus infections were performed as described 
previously (33). Adenovirus was generated using 
the pAdEasy XL adenoviral vector system 
(Stratagene, La Jolla, CA) based on manufacturer’s 
instructions. Then the virus was amplified using the 
following procedures: HEK293A cells were 
infected with adenovirus for 3 days, harvested, re-
suspended in 1 ml sterile PBS, and lysed by four 
rounds of freeze/thaw using a dry ice-methanol 
bath and a 37°C water bath. The supernatant was 
collected after centrifugation at 12000g for 10 
minutes as virus stocks and stored in -80°C. p53 
shRNA construct was transfected into the cells 
with Lipofectamine 2000 reagent (Invitrogen). 
Puromycin (Clontech) was used to select single 
positive clones after transfection using the method 
described before (33). After 2 months’ selection, 
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monoclones were picked up and p53-deleted stable 
cell lines were generated. 
Western blotting—After cells were lysed in 
TBSN buffer（20mM Tris, pH8.0, 150mM NaCl, 
1.5mM EDTA, 5mM EGTA, 0.5% Nondiet P-40, 
0.5mM Na3VO4） complemented with protease 
inhibitors (Sigma), Western blotting were 
performed with antibodies against cleaved-PARP 
(AB3565; Millipore)， total PARP（9542P;Cell 
Signaling） , pAKT (4060;Cell Signaling), AKT 
(9272; Cell Signaling), pS6(4858; Cell Signaling ), 
S6(2217; Cell Signaling), Plk1 (sc-17783; Santa 
Cruz), β-actin (A5441; Sigma), α-tubulin (T6199; 
Sigma), Erk2 (sc-154; Santa Cruz), Redd-1 
(10638-1-AP; Proteintech), p53 (sc-126; Santa 
Cruz) and PKM2 (3198; Cell Signaling).  
Cell viability assay—Cells were grown in 96-
well plates, and viable cell numbers were 
determined by assaying conversion of MTT to 
formazan. The IC50 values were obtained from the 
average viability curves generated by four 
independent measurements of each condition. The 
combination index of BI2536 and metformin was 
measured with the following equation: c.i. = 
(Am)50/(As)50 + (Bm)50/(Bs)50, where (Am)50 is the 
IC50 of metformin in the combination with half of 
the concentration of BI2536 IC50, (As)50 is the 
concentration of metformin that will produce the 
identical level of effect alone, (Bm)50 is the IC50 of 
BI2536 in the combination with half of the 
concentration of metformin IC50 and (Bs)50 is the 
IC50 of BI2536 after single administration. 
Antagonism is indicated when c.i.>1, c.i.=1 
indicates an additive effect and a c.i.<1 indicates 
synergy. 
Glucose/Lactate assays—Glucose consumpt
ion and lactate production were calculated by 
measuring the remaining glucose and lactate i
n the cell culture medium using Eton Bioscien
ce glucose and L-lactate assay kits following t
he procedures described by the manufacturer. 
Intracellular ATP measurement—Control a
nd treated cells were counted and then harvest
ed for testing intracellular ATP level followin
g the procedure described by the manufacturer
 (Roche). 
α-ketoglutarate assay—α-ketoglutarate level 
in cultured cells was measured using BioVision α-
ketoglutarate colorimetric assay kit following the 
procedure described by the manufacturer. 
Colony formation assay—500-1000 Cells 
were seeded in 6-well plates and cultured with 
medium or medium containing different drugs for 
20 days with medium refreshment every two days. 
After culturing, cells were fixed using 10% 
formalin and stained with 0.5% crystal violet, then 
colony numbers were counted. 
FACS analysis—Cells were harvested by 
trypsination, fixed in 75% ethanol, stained with 
propidium iodide solution at a final concentration 
of 50 μg/ml, and then subjected to fluorescence-
activated cell sorting (FACS) analysis. 
Mouse xenograft model—LNCaP cells (5 X 
106 cells per mouse) were mixed with an equal 
volume of Matrigel (Collaborative Biomedical 
Products) and inoculated into the right flank of 24 
athymic nude mice (Harlan Laboratories). One 
week later, the mice were randomly separated into 
4 groups (6 mice in each group). At day 17 after 
implantation, castration was performed with all the 
24 mice. Metformin was dissolved in distilled 
water and given to the mice using gavage. BI2536 
was dissolved in 0.1 N HCl, diluted with 0.9% 
NaCl, and injected into the tail vein. Both drugs 
were injected twice a week for 10 weeks during 
which body weights and tumor volumes were 
followed. Tumor volumes were estimated using the 
formula: V=L X W2/2(V, mm3; L, mm; W, mm). The 
length and width were measured using digital 
calipers twice a week. 
Patient-derived xenograft model—Mice 
carrying LuCaP35CR tumors were obtained from 
Dr. Robert Vessella at University of Washington 
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(34). Tumors were amplified by cutting the original 
tumors into about 20~30 mm3 pieces and then 
implanted into pre-castrated nude mice. After 
amplifying enough tumors, tumors were harvested 
and cut into about 20~30 mm3 pieces before 
implanting into 16 pre-castrated nude mice. When 
tumors reached 250 to 300 mm3, mice were 
randomly separated into 4 groups (4 mice in each 
group) for different treatments.  
Serum PSA measurement—Blood was coll
ected from mice by retro-orbital bleeding once
 a week for determine the serum PSA level. 
PSA level was measured using PSA (Human) 
ELISA kit (KA0208; Abnova) following the p
rocedure described by the manufacturer. 
Tumor Western blotting—Tumors were 
harvested and frozen in -80°C before conducting 
further analysis. For Western blotting, tumors were 
melted on ice and homogenized using RIPA buffer 
(150mM NaCl, 1mM PMSF, 1mM EDTA, 1% 
Triton X100, 0.1% SDS) complemented with 
protease inhibitors (Sigma). Then proteins were 
detected using specific antibodies following the 
procedure described above. 
Statistical analysis—Standard 2-tailed Stud
ent t tests were performed to determine the si
gnificance of differences between experimental 
conditions and treatments. 
 
RESULTS 
Inhibition of Plk1 and metformin decrease 
viability and colony formation of PCa cells 
synergistically— To test whether inhibition of Plk1 
synergizes with metformin in inhibiting PCa cell 
proliferation, we conducted cell viability assays to 
calculate the combination indices of metformin and 
BI2536, a well-recognized Plk1 inhibitor, in two 
PCa cell lines: androgen dependent LNCaP and 
LNCaP-derived but androgen-independent C4-2. 
Combination indices of two drugs in both cell lines 
are about 0.4, suggesting that the two drugs act in a 
synergistic manner in both cell lines (Tables 1, 2). 
To further confirm these initial observations, we 
performed extensive Western blotting analysis to 
follow the protein level of cleaved-PARP, a marker 
for apoptosis. Consistent with the cell viability 
assays, we found that in both LNCaP and C4-2 
cells there is a significantly increased level of 
cleaved-PARP after the cells were treated with 
both metformin and BI2536 in comparison to the 
monotherapy (Fig. 1A-C). However, we did not 
observe a similar result in PC3, a p53-null PCa cell 
line (Fig.1D). More importantly, we also found that 
these two drugs, either working alone or together, 
failed to induce detectable apoptosis in non-
transformed prostate epithelial cell RWPE-1 (Fig. 
1E). Finally, we also found that B2536 and 
metformin act synergistically to inhibit colony 
formation of LNCaP (Fig. 1F) and C4-2 cells (Fig. 
1G). 
 
Plk1 status affects cellular response to 
metformin—Because inhibition of Plk1 potentiated 
metformin-mediated inhibition of proliferation in 
LNCaP and C4-2 cells, two PCa cell lines with 
elevated levels of Plk1, we then asked whether 
overexpression of Plk1 in RWPE-1, which has an 
almost non-detectable level of Plk1, affects its 
response to metformin. Accordingly, we 
overexpressed Plk1 in RWPE-1 cells by infecting 
with adenovirus. One immediate outcome of Plk1 
overexpression in RWPE-1 cells is the activation of 
the PI3K/AKT/mTOR cell survival pathway, as 
indicated by the increased phosphorylation levels 
of AKT and S6, two major downstream effectors of 
PI3K (Fig. 2A). Plk1 elevation-mediated activation 
of the PI3K/AKT/mTOR pathway is addressed in 
detail in a separate study (35). Interestingly, we 
observed that Plk1 overexpression renders RWPE-
1 cells, which normally do not respond to even very 
high concentrations of metformin, to be much more 
sensitive to this drug (Fig. 2B and 2C). And this is 
not due to the cell cycle effect because Plk1 
overexpression does not change the cell cycle of 
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RWPE-1 cells (Fig. 2D). In contrast, we found an 
opposite trend in prostate cancer cell line LNCaP, 
i.e., Plk1-depleted LNCaP cells (Fig. 2E) were 
much more sensitive to metformin than control 
cells with a normal Plk1 level, indicated by both 
cleaved-PARP Western blotting (Fig. 2F) and cell 
viability assays (Fig. 2G). Importantly, the 
increased cell death is not due to the Plk1 inhibition 
itself as cells infected with Plk1 depletion virus did 
not have a significant higher apoptosis level 
compared with the cells infected with control virus 
(Fig. 2H). In addition, the protein level of Redd-1, 
which was induced after high concentrations of 
metformin treatment (18), was much lower in Plk1-
overexpressed cells than in Plk1-depleted cells (Fig. 
2E). Furthermore, Plk1 depletion also potentiates 
metformin-associated cell death in C4-2 cells (Fig. 
2I). Consistent with the observation in Fig. 2E, we 
found that co-treatment with BI2536 further 
enhanced the level of Redd-1 induced by 
metformin in LNCaP cells, but not in PC3 and 
DU145 (Fig. 2J), both of which do not have wild 
type p53. Taken together, these data suggest that 
the roles of Plk1 in cellular responses to metformin 
are different between prostate cancer cells and non-
transformed prostate epithelial cells. And p53 
status may play an important role in the cellular 
response to the combination treatment of Plk1 
inhibition and metformin. 
 
Metformin and BI2536 induce a p53-
dependent apoptosis—Because p53 is likely 
involved in mediating the synergic effect of 
BI2536 and metformin and because a p53-
dependent synergy between metformin and 2-
deoxyglucose was reported previously (36), we 
asked whether the p53 level was changed upon 
BI2536 and metformin treatment. Although we did 
not detect any obvious change of p53 level in 
LNCaP cells using the lower drug concentrations 
(Fig. 3A), a significant increase of p53 level of 
combinational treatment than single drug 
treatments was observed when we increased the 
concentrations of both metformin and BI2536 to 
about their IC50 values (Fig. 3B). Furthermore, the 
combinational treatment led to a significant 
increase of the p53 level in C4-2 cells even at the 
lower concentrations (Fig. 3C). Of note, we 
repeatedly noticed that C4-2 cells were much more 
sensitive to BI2536 than LNCaP cells during the 
experimentation, suggesting that Plk1 is much 
more critical for CRPC cell survival. Next, to 
further validate whether p53 is important for the 
combinational effect, we generated several p53-
depleted LNCaP cell lines (Fig. 3D) and tested their 
sensitivities to different drug treatments. 
Comparing with WT LNCaP cells, p53-depleted 
LNCaP cells showed similar sensitivities to either 
metformin or BI2536 alone, but much less sensitive 
to combinational treatment, as indicated by cell 
viability after drug treatments (Fig. 3E). Consistent 
with this observation, we found that there was a 
significant decrease of the level of cleaved-PARP 
in p53-depleted LNCaP cells than in control cells 
under the same combination treatment (Fig. 3F). 
Furthermore, we conducted colony formation assay 
to confirm the results (Fig. 3G and 3H). 
 
BI2536 hinders glycolysis and glutamine 
anaplerosis induced by metformin—As metformin 
actively participates in many important metabolic 
pathways, we investigated the changes of cellular 
metabolism after adding Plk1 inhibitor together 
with metformin. Similar to previous reports on the 
effect of metformin on glycolysis, we found that 
metformin treatment significantly up-regulated 
glucose consumption and lactate production in 
LNCaP cells (Fig. 4A), whereas addition of BI2536 
down-regulated metformin-induced glycolysis, 
indicated by the decrease of glucose consumption 
and lactate production (Fig. 4B). Mechanistically, 
metformin treatment increased the level of 
pyruvate kinase M2 (PKM2), a rate-limiting factor 
of glycolysis, in LNCaP cells, but addition of 
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BI2536 antagonized such an effect (Fig. 4C). 
Recently, glutamine anaplerosis was found to be 
another important cell survival pathway after 
metformin treatment (37). Thus, we asked whether 
Plk1 inhibition has any effects on glutamine 
metabolism as well. Upon a high concentration of 
metformin (2.5mM) treatment, the majority of 
cellular α-ketoglutarate is generated from 
glutamine, but not from the glucose metabolism in 
PCa cell lines (37). We investigated whether 
BI2536 inhibits glutamine anaplerosis by 
measuring cellular α-ketoglutarate level under this 
condition. As expected, treatment with 2.5mM 
metformin up-regulated glutamine anaplerosis in 
LNCaP cells, but adding BI2536 together 
significantly antagonized this effect (Fig. 4D). 
Taken together, these data suggest that inhibition 
of Plk1 negatively affects the two crucial cellular 
anti-stress metabolic responses induced by 
metformin treatment, consequently resulting in 
rapid cell death due to energy crisis. 
 
BI2536 and metformin acts synergistically in 
LNCaP xenograft model—To assess the in vivo 
effect of metformin and BI2536 treatment, alone or 
in combination, we conducted LNCaP xenograft 
model study. In order to mimic the progression of 
tumors into androgen-independent stage, we 
performed castration to the mice after detectable 
tumors were formed. As indicated in Fig. 5A, 5B 
and 5D, neither metformin nor BI2536 treatment 
alone had an obvious effect in preventing the tumor 
growth whereas a strong inhibition of tumor 
growth was detected in the combinational group, 
supporting a synergistic effect of metformin and 
BI2536 in vivo. Moreover, the trend was similar to 
tumor volume measurements when the serum 
prostate specific antigen (PSA) levels of these mice 
were followed (Fig. 5C). 
 
BI2536 and metformin acts synergistically in 
a patient-derived xenograft model—To better 
mimic the tumor growth condition and follow the 
situation in the relatively late CRPC stage, we 
conducted a patient-derived xenograft study using 
LuCaP35CR model, which was originally 
generated form a 66-year-old patient (34). Of note, 
this model is not indicated to harbor any p53 
mutation in a whole-exome sequencing study of the 
LuCaP series (38). After about 40 days drug 
treatment, we found that metformin treatment 
alone nearly had no effect and that BI2536 alone 
showed a very limited effect in inhibiting the tumor 
growth. In contrast, we observed a significantly 
lower growth rate of the tumors treated with both 
metformin and BI2536 in comparison with 
monotherapies (Fig. 6A, 6B and 6D). Importantly, 
this result was also consistent with the serum PSA 
levels and Western blotting analysis of the 
harvested tumors (Fig. 6C and 6E). Thus, these 
experiments support the notion that BI2536 and 
metformin also have a strong synergy in a patient-
derived xenograft model. 
 
DISCUSSION   
Metformin, with its high safety and 
remarkable functions in inhibiting growth of 
multiple tumor cell lines, favors physicians to 
consider its potential use in the treatment of cancer. 
However, in addition to the undefined molecular 
action, there are many other concerns about the 
dose and cellular uptake of the drug when 
considering the clinical applications. Thus, how to 
achieve the anti-neoplastic function with 
recommended therapeutic dosages for diabetic 
patients or even lower dosages for non-diabetic 
patients is one challenging task for physicians. 
Herein, we presented a novel therapeutic strategy 
which can dramatically increase the efficiency of 
metformin in inhibiting the growth of PCa by 
combining inhibition of Plk1. 
Beyond the well identified cell-cycle related 
functions, Plk1 also plays important roles in many 
pivotal signaling pathways of cancer cells. In 
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addition to the previous finding that Plk1 acts as a 
negative regulator of p53, we also showed that Plk1 
contributes to activation of the PI3K/AKT/mTOR 
pathway (Fig. 2A), one of the most frequently 
activated cell surviving pathways in numerous 
cancer cells (39-41). Thus, we proposed to 
challenge the hypothesis that Plk1 inhibition could 
potentially be one novel avenue to increase 
metformin’s efficiency against PCa. 
First of all, we found that Plk1 inhibitor 
BI2536 and metformin showed a strong synergy in 
LNCaP cells and its androgen-independent 
derivative C4-2 cells (42), as we noticed that 
BI2536 strikingly increased metformin-associated 
lethality in these two cell lines. For LNCaP cells, 
we can even use about 5 µM to induce apoptosis 
and prevent colony formation when combing with 
a low concentration of BI2536 (Fig. 1B, 1F). The 
other interesting observation is that C4-2 cells were 
much more sensitive to Plk1 inhibition (IC50 of 
8nM) than LNCaP cells (IC50 of 90nM) even they 
share the same genetic background (Table 2, Fig. 
1C, 1G), suggesting that Plk1 plays more and more 
important roles as PCa cells progress to castration-
resistant stage. In contrast, normal prostate cells 
were quite resistant to these two drugs (Fig. 1E and 
2C), thus offering selectivity for this proposed 
therapeutic strategy against cancer cells. Consistent 
with these observations, Plk1 depletion sensitized 
LNCaP cells to low concentrations of metformin 
(Fig. 2F and 2G). Furthermore, we observed that 
overexpression of Plk1 in RWPE-1 cells somehow 
made these non-transformed cells more sensitive to 
metformin (Fig. 2B and 2C). Consistent with our 
previous findings that Plk1 negatively regulates 
p53, we found that p53 was indeed down-regulated 
when we overexpressed Plk1 (Fig. 2B, bottom 
panel). However, a significant induction of p53 
was observed in the Plk1-overexpressing RWPE-1 
cells upon metformin treatment (Fig. 2B, top panel). 
One possible explanation is that Plk1 
overexpression changes the cellular signaling 
network, such as the PI3K/AKT/mTOR pathway, 
in normal prostate epithelial cells, somehow makes 
them behave like cancer cells, which are more 
sensitive to metformin, and that p53 induction 
correlates with the onset of apoptosis. 
Although mitochondrial inhibition acts as the 
premise for metformin’s downstream functions is 
well-accepted, the notion that the drug exerts its 
anti-tumor functions through the AMPK pathway 
is plausible as alternative pathways are supported 
by increasing evidences. Particularly in PCa, 
activation of the p53/Redd-1 axis was found to be 
crucial in inhibition of both cell cycle progression 
and mTOR pathway (18). Even though the exact 
role of p53 in metformin treatment is still under 
debate as opposite results were observed in colon 
cancer (43), we don’t feel that these two 
observations actually counteracted with each other. 
Because colon cancer cells without p53 cannot 
efficiently make metabolic alternations in response 
to the mitochondrial stress induced by metformin, 
they are more sensitive to metformin than colon 
cancer cells with WT p53 (43). However, for the 
p53/Redd-1 axis in PCa cells carrying WT P53, 
positive regulation of p53 will lead to an enhanced 
repression of cell proliferation. Indeed, after 
LNCaP and C4-2 cells were co-treated with 
BI2536 and metformin, the p53 and Redd-1 levels 
are both up-regulated (Fig. 2J, Fig. 3B and 3C). 
Since Redd-1 was found to be a potent tumor 
suppressor downstream of p53 (44-46), we propose 
that the up-regulated p53/Redd-1 pathway could be 
one of the explanations for the observed synergy in 
PCa. Consistently, we found that p53 knockdown 
makes LNCaP cells significantly less sensitive to 
the combination treatment of BI2536 and 
metformin although we haven’t figured out the 
exact molecular mechanism (Fig. 3E-3G). 
Interestingly, we also found that BI2536 treatment 
significantly inhibited metformin-induced 
glycolysis and glutamine anaplerosis (Fig. 4B-4D), 
two important cell survival responses upon 
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mitochondrial stress (37,47). Similar to our 
findings, an inhibitor of glycolysis strongly 
synergizes with metformin in PCa cells (36). But 
the difference is that in comparison with metformin 
treatment alone, we did not observe a sharp 
decrease of ATP level when combining metformin 
and BI2536 together (data not shown). In short, we 
propose that inhibition of Plk1 promotes the 
cytotoxicity of metformin to PCa cells through 
both signaling pathways and metabolic pathways. 
Previously, the lowest dose of metformin used in 
mouse xenograft studies was 40 mg/kg per day (23) 
and there was a detectable reduction of tumor 
growth in LNCaP xenograft model using 1 mg/day 
metformin treatment (6). To determine whether we 
could significantly reduce the dose of metformin 
when combining BI2536 treatment together, we 
injected 5 mg/kg metformin for just two times per 
week, which equals to about 0.03 mg/day. Of note, 
the dose of BI2536 was also significantly lower 
than the previously reported dosage in PCa 
xenograft study (48). Upon castration, all the 
tumors of LNCaP xenograft study were growing 
much slower and neither of these two single 
treatments had obvious effect in tumor repression 
compared with the control group. In contrast, the 
tumors treated with both drugs nearly stopped 
growing anymore upon castration (Fig. 5B), 
strongly suggesting that these two drugs act 
together in preventing the progression from 
androgen sensitive to androgen-independent stage. 
LuCaP35CR is the androgen-independent form of 
LuCaP35, a new patient-derived xenograft tumor 
model for studying the progression to androgen 
independence (34). For our purpose, LuCaP35CR 
could be an excellent model to mimic the relatively 
late stage of PCa. Because these tumors grow much 
faster than tumors generated from LNCaP cells, we 
increased the doses of metformin and BI2536 to 30 
mg/kg and 15 mg/kg (2 injections per week), 
respectively. Similar to the LNCaP xenograft study, 
we did not detect any obvious change in single drug 
treatment as both of the doses were still 
significantly lower than what has been generally 
used in mouse studies. In striking contrast, the mice 
treated with both drugs not only had smaller tumors 
and lower serum PSA levels (Fig. 6B and 6C), but 
also showed reduced angiogenesis potentials as the 
tumors became transparent (Fig. 6A).  
In summary, our in vitro and in vivo data 
support a strong synergy of inhibition of Plk1 and 
metformin in inhibiting PCa cell proliferation. In 
addition, we are the first to provide evidence that 
metformin can still achieve its anti-neoplastic 
function at doses significantly lower than those 
used in others’ studies when combing with BI2536. 
Thus, the combinational strategy can be considered 
for clinical trials to increase the efficiency of 
metformin in PCa.
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Figure legends 
FIGURE 1.  BI2536 and metformin inhibit PCa cell proliferation in a synergistic manner. A-E, 
inhibition of Plk1 potentiates the lethality of metformin in p53 WT PCa cells, but not in PC-3 and non-
transformed prostate cells. LNCaP (A, B), C4-2 (C), PC3 (D) or RWPE-1 (E) cells were treated with 
metformin, BI2536 (BI) or both at the indicated concentrations for the indicated time, and harvested for 
immunoblotting (IB) with antibodies against cleaved form of poly(ADP-ribose) polymerase (c-PARP), a 
marker for apoptosis. In E, 50uM sodium arsenite (As) was used as a positive control for cell death. F, 
BI2536 and metformin inhibit colony formation synergistically in LNCaP cells. LNCaP cells (1x103) were 
seeded on soft agar in 6-well plates, treated with 5uM metformin, 10nM BI2536 or both for 3 weeks, and 
stained with 0.005% crystal violet. The bottom panel is quantification results. *p<0.05, **p<0.01. G, 
BI2536 and metformin inhibit colony formation synergistically in C4-2 cells. C4-2 cells (1x103) were 
seeded on soft agar in 6-well plates, treated with 0.5mM metformin, 1nM BI2536 or both for 3 weeks, and 
stained with 0.005% crystal violet. The bottom panel is quantification results. *p<0.05, **p<0.01. 
FIGURE 2. Plk1 status affects the cellular response to metformin. A, RWPE-1 cells were infected with 
adenovirus expressing GFP or GFP-Plk1 for 2 days and harvested for IB with indicated antibodies. B, 
RWPE-1 cells expressing GFP or GFP-Plk1 were treated with 0.5mM metformin for 24h (top panel) or 
directly harvested for IB (bottom panel). C, RWPE-1 cells were infected with lentivirus (empty vector or 
Plk1 overexpression) for 1 day, harvested, and reseeded in 96-well plates under different concentrations of 
metformin for 3 days, followed by cell viability measurement. D, RWPE-1 cells were infected with 
lentivirus for 3 days and harvested for FACS analysis. E, LNCaP cells were infected with lentivirus (empty 
vector, Plk1 overexpression or Plk1 depletion) for 3 days, treated with 5mM metformin for 4h, and 
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harvested. F, LNCaP cells were infected with lentivirus for 2 days and treated with 0.5mM metformin for 
24h. G, LNCaP cells were infected with lentivirus for 1 day, harvested, and reseeded in 96-well plates under 
different concentrations of metformin for 3 days, followed by cell viability assay. H, 5 x105 LNCaP cells 
were seeded in 6-well plates and infected with lentivirus for 3days and then cell viability was measured by 
counting the number of viable cells. I, C4-2 cells were infected with lentivirus for 2 days and treated with 
0.5mM metformin for 24h. J, LNCaP, DU145 and PC3 cells were treated with indicated drugs for 4h.  
FIGURE 3. Inhibition of Plk1 and metformin induce p53-dependent apoptosis. A & B, LNCaP cells 
were treated with lower (A) or higher (B) concentrations of drugs for 24h, and harvested for IB. 
Doxorubicin (Dox) was used as a positive control to induce elevation of p53 level in B. C, C4-2 cells were 
treated with indicated drugs. D, IB of WT and p53-depleted LNCaP cell clone. E, 5X105 LNCaP cells (WT 
or p53-depleted) were seeded in 6-well plates, treated with 0.5mM metformin, 10nM BI or both for 24h,and 
harvested for viability assay. *p<0.05. F, LNCaP cells (WT or p53-depleted) were treated with drugs 
indicated and subjected to IB. G, LNCaP cells (WT and p53-depleted) (1x103) were seeded on soft agar in 
6-well plates, treated with 0.5mM metformin, 10nM BI2536 or both for 3 weeks, and stained with 0.005% 
crystal violet. H, Quantification of the colony numbers. The results were normalized to control group of 
each cell line, *p<0.05. 
FIGURE 4. Metformin and BI2536 alter glucose and glutamine metabolism. A, LNCaP cells were 
treated with metformin for 24h. After cell numbers were counted, the media were collected to measure 
glucose consumption and lactate production upon normalizing the cell numbers. **p<0.01. B, LNCaP cells 
were treated with 0.5mM metformin, 10nM BI2536 or both for 24h. After cell numbers were counted, the 
media were collected to measure glucose consumption and lactate production. *p<0.05, ***p<0.001. C, 
 at Indiana U
niversity School of M
edicine on July 1, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
16 
 
LNCaP cells were treated with 0.5mM metformin ± 10nm BI2536 for 24h. D, LNCaP cells were treated 
with drugs indicated for 24h and harvested to measure -ketoglutarate levels. 
FIGURE 5. BI2536 and metformin inhibit growth of LNCaP-derived tumors synergistically. LNCaP 
cells (5x106) were subcutaneously inoculated into the flanks of Nu/Nu nude mice to form tumors. Mice 
were castrated at day 17, intravenously injected twice per week with BI2536 (5 mg/kg), given metformin 
(5 mg/kg) using gavage or both, and followed for 75 days. A, images of the mice at the end of the study. B, 
tumor growth curves of the study. C, inhibition of PSA level by BI2536 and metformin. Blood was collected 
beginning from day 30 (once a week) and serum PSA level was measured using the PSA ELISA kit for 6 
weeks. D, tumor weight measurement upon sacrifice. 
FIGURE 6. BI2536 and metformin inhibit LuCaP35CR xenografts synergistically. LuCaP35CR tumors 
were inoculated into nude mice, which had been castrated 2 weeks ahead. After tumors reached the size of 
250 to 300mm3, mice were intravenously injected twice per week with BI2536 (30 mg/kg), given metformin 
(15 mg/kg) using gavage or both, and followed for additional 43 days. A, images of the mice at the end of 
the study. B, tumor growth curves of the study. C, serum PSA level of the mice. D, tumor weight 
measurement upon sacrifice. E, IB of the harvested tumor samples. 
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TABLES 
Table 1: The IC50 values of BI2536 and metformin in LNCaP cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drugs  IC50 Notes 
 
 
 
Combination 
Index=0.384 
BI2536 91.3nM 
metformin 5mM 
BI2536 (in 
combination 
with 2.5mM 
metformin) 
35nM 
metformin(in 
combination 
with 50nM 
BI2536 
5.5uM 
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Table 2: The IC50 values of BI2536 and metformin in C4-2 
 
 
 
 
 
Drugs IC50 Notes 
 
 
Combination 
Index=0.374 
BI2536 8nM 
metformin 5mM 
BI2536 (in 
combination 
with 2.5mM 
metformin) 
2.2nM 
metformin(in 
combination 
with 4nM 
BI2536 
495 uM 
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